Ethyl (S)-2-((4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)-2-oxoacetate

Catalog No. :
ACKTMS341
CAS No. :
2803420-62-2
Molecular Formula :
C22H20ClFN4O5
Molecular Weight :
474.88

IUPAC Name:ethyl (S)-2-((4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)-2-oxoacetate

Ethyl (S)-2-((4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)-2-oxoacetate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$80.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameEthyl (S)-2-((4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)-2-oxoacetate
IUPAC Nameethyl (S)-2-((4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)-2-oxoacetate
Molecular FormulaC22H20ClFN4O5
Molecular Weight474.88
SMILESCCOC(=O)C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1
InChI KeyZXYDHJNWDIATAJ-ZDUSSCGKSA-N
Synonym(S)-Ethyl 2-((4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)-2-oxoacetate (Afatinib Impurity);Impurity CSZ
CAS No.2803420-62-2

Synthetic Route by SureRoute

1. ACKTMS341 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACMBFQ659 route compound structure diagram
    ACMBFQ659314771-76-1 In Stock
  4. Then
  5. ACKTMS341 route product structure diagram
    ACKTMS3412803420-62-2
Inquiry

2. ACKTMS341 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACRWJP426 route compound structure diagram
    ACRWJP42686087-24-3 In Stock
  4. Then
  5. ACKTMS341 route product structure diagram
    ACKTMS3412803420-62-2
Inquiry

Comments (0)